Skip to content
Screener

Vir Biotechnology, Inc. VIR Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$1.16M0.0%
Biohaven logo
BiohavenBHVN

Other financials

Income statement

See full
Revenue$238.9M+19,583%
Gross profit$238.9M+19,763%
Operating income$73.5M+162%
Net income$80.1M+172%
EPS (diluted)$0.47+159%

Balance sheet

See full
Cash & equivalents$287.6M-6.1%
Total debt$93.3M-8.8%
Total equity$982.5M+3.7%
Total assets$1.2B+1.9%

Cash flow

See full
Operating cash flow-$132.4M-69.5%
CapEx$32.0K-98.7%
Free cash flow-$132.8M-66.5%

Valuation

See full
Market cap$1.5B+153%
Enterprise value$1.31B+235%
P/S-26.3×

Profitability

See full
Gross margin96.1%-2.7pp
Operating margin-92.4%-45.5pp
Net margin-83%-40.9pp
FCF margin-686.5%-273pp

Returns & leverage

See full
Return on equity-26.1%-7.9pp
Debt / equity0.1×0.0×
Current ratio-1.0×

Where this comes from

Reported directly by Vir Biotechnology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053549
Line itemJune 30,2026December 31,2025
TOTAL LIABILITIES232,313237,547
Commitments and contingencies (Note 7)
STOCKHOLDERS’ EQUITY:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; no shares issued and outstanding as of June 30, 2026 and December 31, 2025
Common stock, $0.0001 par value; 300,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 169,185,671 and 139,474,954 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively1714
Additional paid-in capital2,230,4641,965,090
Accumulated other comprehensive loss(4,602)(2,057)
Accumulated deficit(1,243,386)(1,197,771)

Item 1. Financial Statements (unaudited)

FAQ

What is Vir Biotechnology, Inc.'s preferred stock, shares authorized?
Vir Biotechnology, Inc. (VIR) reported preferred stock, shares authorized of $10M in Q2 2026.
How has Vir Biotechnology, Inc.'s preferred stock, shares authorized changed year-over-year?
Vir Biotechnology, Inc.'s preferred stock, shares authorized decreased by 0.0% year-over-year, from $10M to $10M.
What is the long-term trend for Vir Biotechnology, Inc.'s preferred stock, shares authorized?
Over 3 years (2022 to 2025), Vir Biotechnology, Inc.'s preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $10M to $10M.
What does preferred stock, shares authorized mean?
Preferred Stock, Shares Authorized

Ask your AI about Vir Biotechnology, Inc.'s preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude